OMER Peter A Demopulos MD buys $104K worth of shares
Jan 02, 2026, 11:37 AM
0.00%
What does OMER do
Omeros, a Seattle-based biopharmaceutical company with 198 employees, focuses on developing therapeutics for immunologic disorders and is advancing several candidates, including narsoplimab and OMS527, in clinical trials. The company went public on October 8, 2009.
Peter A Demopulos MD bought 21,000 shares of OMER on 16 May at $4.95 per share, worth a total of $104K. They now own 139,421 OMER shares, or a 18% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.